A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. - Wikidata - wikimedia - TriplyDB

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

http://www.wikidata.org/entity/Q37141237

about

Adoptive immunotherapy against ovarian cancer Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects.Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells Natural killer cells in human cancer: from biological functions to clinical applications Genetic barriers in transplantation medicine Utilizing chimeric antigen receptors to direct natural killer cell activity Understanding of molecular mechanisms in natural killer cell therapy NK cells in therapy of cancer Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer Minireview: Regulatory T Cells and Ovarian Cancer.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.NK cell-based immunotherapy for malignant diseases.Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Enhancement of natural killer cell cytotoxicity by sodium/iodide symporter gene-mediated radioiodine pretreatment in breast cancer cells Natural killer cell-based therapies.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.NK cells: immune cross-talk and therapeutic implications.NK cell-based immunotherapies in Pediatric Oncology.Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial.Present and Future of Allogeneic Natural Killer Cell Therapy Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Trial Watch: Adoptive cell transfer immunotherapy.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Biological role of NK cells and immunotherapeutic approaches in breast cancer.Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

P2860

Q26748905-735F8BC3-DF3B-461F-9CF6-D906AB6A5BC6 Q26765115-1CD4CF26-9A6C-4021-A138-E1FF8ECA9F60 Q26773135-FF7D938E-B46D-4489-99F8-3227FDCB7828 Q26774678-F5E18A9F-6D03-4953-9D99-6C23E418D56F Q26781260-6E502F08-7B85-42BB-A09D-62195ECF00DB Q26996660-230FC3E1-34E8-4768-84E4-71DC46A86371 Q27301956-F930BB54-90D3-4C26-8D0C-3C50F2F9BB8B Q27309991-D4B62005-3D5D-4549-BC04-59E173CC0E45 Q27691427-0ABAD531-B984-43F4-A574-E4BB1DE60BA8 Q28069956-9C20B2E7-BD55-40D1-AE3C-574E66D273C1 Q28082868-6C11A37A-C701-4365-B033-A66728A2FE1F Q28086976-E363D3D3-53CE-4F10-A69C-A54406004EAD Q28242241-90F21F3A-EC9F-43C9-AE28-873AA97E0A6A Q28266580-DB23D5F8-D018-4AB4-8F16-7C654C81C6CE Q30244214-29459ADB-098B-4BF3-A811-D30B60200CA8 Q33357295-179FD09E-E9C7-4D9C-9513-206C969BD568 Q33748308-9B5561C2-41A4-434B-A255-A6605E5EB948 Q33781150-4CB3C72D-679F-4FE7-A8F7-510D436013E6 Q33827433-95E81F2E-FE8E-4E09-BAA4-0100DB7F0B2C Q33905311-808EC130-B0FB-4F03-9E71-EDD12D84E431 Q33922539-2DAD7BD4-1797-4A1E-818F-B36E72E8F61D Q34180695-63F8DA20-E05F-4825-893E-928D10CA5D04 Q34307792-2AFC9A74-26B4-4300-91DE-448618BA3B11 Q34934718-0B8B8943-B71D-4062-A078-2548C9EADED4 Q34988727-A98FF1A7-B91D-43EA-9BA8-54F6B5369FDB Q35177618-F9DA395D-E470-4D13-A752-A402AB5C3F5B Q35269067-9D3CDCB7-10E1-4B74-99D9-2C4EDC812839 Q35510507-5802BC9A-9807-49C1-99E2-8B9E38156AC9 Q35591444-00B02CE7-2B95-40FC-AA30-02AB55CE3903 Q35600975-63E6F5D2-9ACC-4963-9CB6-30AA1E2725EA Q35660263-7D7C8F97-7EC4-4994-9463-63F2C23490EA Q35677351-4735223C-4816-4167-9DF0-2E6CCDFEDD34 Q35752181-46474A29-FDB8-4DF1-8A17-34B5E12E58EE Q35963440-5473ECE3-A396-42B4-9E96-EFA671DA3F06 Q36057432-5A03D025-3F07-4062-953A-F12B6699E50A Q36245682-A640B675-D9E1-4E3F-A121-49651CC3111C Q36261159-B975FD25-EF1E-4CE2-A191-56384FD794B3 Q36460884-C1EC73B6-EADA-4BA8-87DC-98668B6CFC9F Q36463830-7CFBB714-EC5B-4C9F-9949-03E097FCBE13 Q36478280-61E00257-3F94-4F8D-9FE6-F977B237D40F

P2860

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

http://www.wikidata.org/entity/Q37141237

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@en

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@nl

type

label

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@en

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@nl

prefLabel

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@en

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@nl

P1433

Q37141237-55776C1B-EFF2-42EF-90B5-9D26491A6245

P1476

Q37141237-E0C959C1-2955-4D7C-8A25-D6CA35352032

P2093

Q37141237-015ACD66-76E4-45A7-A37F-C9EABFF78E5C

Q37141237-1217FBBF-E033-4B33-8473-C2B74C3B5FCD

Q37141237-31603925-B347-41AB-9AF2-109F0A4B6B87

Q37141237-4C2A2598-1D6B-402D-AD9B-D11C140F456B

Q37141237-6B03EC58-43B1-44F7-93A8-2E0BF3478A5B

Q37141237-760463F7-AEF5-4B0F-9A1B-622D54C746D7

Q37141237-906243F7-7BB1-4115-AC97-ECCD49F38D7F

Q37141237-CAD176CA-E16A-4306-B6D3-C4E89DA3B71D

Q37141237-CFA7E3C7-F071-4864-A277-E5A1E58112BE

Q37141237-D6C00ABD-ABC6-4064-BBA1-08F04FC16C24

P2860

Q37141237-056DDC51-80BB-4BB1-AD95-5D7F104160D2

Q37141237-09B6CD3A-2F8F-4277-BEE0-E9E283F9B9F5

Q37141237-100A986E-08B3-4FFB-B434-4FE549080F59

Q37141237-10272260-E9D6-4AE7-9230-2C7CBA32A0CF

Q37141237-1200DEF7-726E-40E0-9346-45CC59237B38

Q37141237-1334B609-7E52-4271-8D8D-E047081BC15E

Q37141237-2013E2E5-C3DD-4797-A218-FE7ADC1B09CB

Q37141237-268817A8-2577-4FA3-9317-2F308F0BBF42

Q37141237-2B3F126D-87C4-4530-BCDC-3DA34C1A248C

Q37141237-392FDA99-3748-48B0-AD4F-29086949D5DB

P304

Q37141237-C664E869-2FFF-4797-B72B-34025E56EC9D

P31

Q37141237-50E6A58A-BAFA-422B-806F-078C3D98740D

P356

Q37141237-5020BD6F-98F0-42C7-9DB1-30A94C66DD6F

P433

Q37141237-D4FE88E2-7121-4B6E-B74A-597DA2070D92

P478

Q37141237-9E46B040-A004-4AE8-B35D-FBA7E50C9AA9

P50

Q37141237-4AB3FC3E-E7F4-4E3E-BB1B-BD7E43F7716B

P577

Q37141237-A84E765C-1412-49E6-8527-2D3E195FDCAB

P698

Q37141237-30528B8B-58AF-467B-A464-BBE0CA7A7723

P921

Q37141237-87A50672-8AC2-4819-8ECE-AF16338F2814

P932

Q37141237-86E024AA-5B35-4D24-B0D6-BFDB087046FC

P356

14653249.2010.515582

P1433

P1476

A phase II study of allogeneic ...... ent ovarian and breast cancer.

@en

P2093

Amy L Jonson

http://www.w3.org/2001/XMLSchema#string

David McKenna

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Miller

http://www.w3.org/2001/XMLSchema#string

Julie Curtsinger

http://www.w3.org/2001/XMLSchema#string

Kathryn Dusenbery

http://www.w3.org/2001/XMLSchema#string

Levi S Downs

http://www.w3.org/2001/XMLSchema#string

Linda F Carson

http://www.w3.org/2001/XMLSchema#string

Melissa A Geller

http://www.w3.org/2001/XMLSchema#string

Patricia L Judson

http://www.w3.org/2001/XMLSchema#string

Peter A Argenta

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Strategies to overcome obstacles to successful immunotherapy of melanoma

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

T cell homeostasis and systemic autoimmunity

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

P304

98-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/14653249.2010.515582

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Angela Panoskaltsis-Mortari

P577

2010-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20849361

http://www.w3.org/2001/XMLSchema#string

P921

P932

3760671

http://www.w3.org/2001/XMLSchema#string